Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market
Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations. Effective July 1, 2025, Lupin has formally carved out its consumer-facing division—LupinLife Consumer Healthcare Ltd. (LCH)—as a wholly owned subsidiary. This move is designed to sharpen the company’s focus on the growing self-care segment in India, signaling Lupin’s long-term commitment to expanding its presence in the country’s burgeoning over-the-counter (OTC) health and wellness market.
LupinLife was originally launched in 2017 as Lupin’s dedicated consumer healthcare arm. Over the years, it has developed into a strong player in the Indian OTC space, offering scientifically backed, trusted wellness and nutritional products. The company’s portfolio includes popular brands like Softovac® (a fiber-based digestive health supplement), Beplex Forte® (a vitamin B-complex supplement), Corcium® (a calcium and vitamin D3 supplement for bone health), and Aptivate® (a natural appetite stimulant for children and adults). These products have gained wide consumer trust and are integral to LupinLife’s growing brand equity.
With the formal carve-out into a separate legal entity, Lupin aims to unlock the full potential of its consumer healthcare business by enabling greater operational autonomy, focused strategic investments, and enhanced agility in product development and market execution. The new structure will allow LupinLife to act with the independence needed to compete in the dynamic and fast-moving consumer health landscape, which demands innovation, marketing prowess, and deep consumer engagement.
Veteran business leader Anil Kaushal will assume the role of Chief Executive Officer for the newly formed subsidiary. Under his leadership, LCH is expected to accelerate its growth trajectory through brand expansion, geographic reach, and new product innovation tailored to the evolving needs of Indian consumers. Kaushal’s experience in driving growth across fast-moving consumer health categories is anticipated to be instrumental in scaling LCH’s offerings in both urban and rural India.
Commenting on the development, Nilesh Gupta, Managing Director of Lupin, emphasized the company’s strategic intent behind the move. “This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LupinLife Consumer Healthcare exemplifies our unwavering dedication to patient-centric care and service to consumers,” he said. He further noted that this structure will allow the business to operate with a consumer-first mindset, responsive to market changes and attuned to evolving wellness trends.
Echoing this sentiment, Anil Kaushal, CEO of LCH, remarked, “This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India.”
India’s OTC and self-care market has witnessed significant growth over the past decade, driven by increasing health awareness, rising disposable incomes, and a shift toward preventive healthcare. As consumers increasingly seek convenient and reliable health solutions outside of traditional prescription channels, Lupin’s renewed emphasis on its consumer healthcare vertical through LCH is both timely and strategically aligned with market trends.
By empowering LupinLife to function independently, Lupin is positioning itself to capitalize on India’s expanding wellness economy, compete more effectively with established consumer healthcare brands, and chart a path of accelerated innovation and brand loyalty. The carve-out marks a pivotal milestone in Lupin’s long-term diversification strategy and reinforces its focus on delivering healthcare solutions beyond the clinical setting.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
